News
CBAY
32.48
0.00%
0.00
UPDATE 1-Gilead posts quarterly loss on acquisition charge, revenue rises 5%
Gilead Sciences posts quarterly loss on acquisition charge, revenue rises 5% on higher HIV, oncology and liver disease treatment sales. Company took $3.9 billion charge for recent acquisition of liver drug developer CymaBay Therapeutics. Shares of Gilead were up 3.3% in after hours trading.
Reuters · 1d ago
Gilead posts quarterly loss, revenue rises 5%
Gilead posts quarterly loss, revenue rises 5% on higher HIV, oncology and liver disease treatment sales. Gilead took a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics. The company's first-quarter revenue rose 5% to $6.69 billion.
Reuters · 1d ago
UPDATE 4-Lazard profit beats estimates as dealmaking rebound fuels record revenue
Lazard's first-quarter profit beats estimates as dealmaking rebound fuels record revenue. Firmwide and advisory revenues surged to record levels. The bank advised on a string of high-profile deals in the first quarter. Lazard's adjusted revenue jumped 42% to $747 million.
Reuters · 1d ago
UPDATE 3-Lazard posts better-than-expected profit on deals, assets boost
Lazard posts better-than-expected profit on deals, assets boost in first quarter. Investment bank's adjusted revenue jumped 42% to $747 million. Firm advised on a string of high-profile mergers and acquisitions in the quarter. Lazard's assets under management rose to $250 billion from $232 billion.
Reuters · 1d ago
UPDATE 2-Lazard posts first-quarter profit on deals, assets boost
Lazard posts first-quarter profit on deals, assets boost. Investment bank's profit boosted by a string of high-profile mergers and acquisitions it advised on in the first quarter. Lazard's assets under management rose to $250 billion in the quarter from $232 billion a year earlier.
Reuters · 1d ago
Weekly Report: what happened at CBAY last week (0318-0322)?
Weekly Report · 03/25 09:10
Cymabay Therapeu: Securities to be offered to employees in employee benefit plans, post-effective amendments
Press release · 03/23 00:25
Cymabay Therapeu: Statement of changes in beneficial ownership of securities
Press release · 03/23 00:25
Gilead completes CymaBay acquisition but negative impact on 2024 EPS
Gilead Sciences has completed its $4.3B acquisition of CymaBay Therapeutics. The biopharma said the deal will reduce the company's 2024 EPS by approximately $3.20. Gilead expects the deal to have a negative impact on 2024 EPS guidance.
Seeking Alpha · 03/22 21:37
*News On CymaBay Therapeutics Inc. (CBAY) Now Under GILD
Dow Jones · 03/22 21:08
CymaBay Therapeutics: Major Acquisition and Leadership Overhaul
TipRanks · 03/22 13:32
*Gilead Sciences Announces Completion Of Acquisition Of CymaBay >GILD CBAY
Dow Jones · 03/22 13:18
Press Release: Gilead Sciences Announces Completion of Acquisition of CymaBay
Gilead Sciences Announces Completion of Acquisition of CymaBay Therapeutics for approximately $4.3 billion in total equity value. Gilead's lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements the company's existing liver portfolio. The company announced the completion of the previously announced transaction to acquire Cyma Bay.
Dow Jones · 03/22 13:18
CymaBay Therapeutics Revamps Executive Compensation Agreements
TipRanks · 03/20 20:32
Weekly Report: what happened at CBAY last week (0311-0315)?
Weekly Report · 03/18 09:10
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences Inc’s plans to increase its production of cell therapy cancer treatments fourfold by 2026. The company says the advancements stem from significant enhancements in its manufacturing processes. Gilead is a subsidiary of Abbott Laboratories, a leading maker of cancer drugs.
Benzinga · 03/15 16:51
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Three stocks in the health care sector are considered to be overbought. The RSI is a momentum indicator that compares a stock's strength on days when prices go up to its weakness. Molina Healthcare, Inc. Is one of the three stocks with a RSI value above 70.
Benzinga · 03/14 12:57
*Gilead Sciences: Required Waiting Period Under the Hart-Scott-Rodino Act With Respect to Gilead's Cash Tender Offer for CymaBay Therapeutics, Inc. Expired on Friday >GILD
Dow Jones · 03/11 12:26
*Gilead Sciences: Other Conditions Remain to Be Satisfied, Including, Among Others, a Minimum Tender of Shrs of Common Stk of CymaBay Representing a Majority of the Total Number of Outstanding Shrs of Common Stk of CymaBay >GILD
Dow Jones · 03/11 12:26
More
Webull provides a variety of real-time CBAY stock news. You can receive the latest news about Cymabay Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. It is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.